Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Profile of [14C]-BTD-001 in Healthy Males
NCT03107013Phase 1Completed
- Sponsor
- Balance Therapeutics, Inc.
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Pentetrazol in idiopathic hypersomnia (IH) and narcolepsy, sponsored by Balance Therapeutics, Inc. Primary endpoints: Mass balance recovery after a single dose of carbon-14 (14C)-BTD-001 at 12 days and Metabolite Profiling at 12 days. Started Apr 2017; status: completed.
02
Drugs
Pentetrazol
03
Conditions
idiopathic hypersomnia (IH)narcolepsy
Beyond the preview
Go deeper on NCT03107013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107013.